Date trial registered
Incorporation of the first participant
Academic title (Source of data: WHO)
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C
Type of trial (Source of data: WHO)
Design of the trial (Source of data: WHO)
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Phase (Source of data: WHO)
Phase 1/Phase 2
Primary end point (Source of data: WHO)
Number of Participants With Abnormal Laboratory Values
Number of subjects with changes on ECG.
Number of subjects with clinically significant changes in vital signs.
Secundary end point (Source of data: WHO)
Area under the plasma concentration-time curve (AUC)
Duration of overall response
Duration of stable disease
Objective response rate
Plasma concentration (Cmax)
Time to achieve Cmax (tmax)
Contact information (Source of data: WHO)
Please refer to primary and secondary sponsors